Thursday, April 15, 2021 Daily Archives

Virus-Like Particle Production in Insect Cells Using the Baculovirus Expression System: Addressing Challenges across the Workflow

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Maya Yovcheva, R&D Scientist, Cell Biology, Chantelle Gaskin, Field Applications Scientist, Purification, and Florian Durst, Sr. Field Application Specialist, Pharma Analytics, Thermo Fisher Scientific Being part of the newer generation of vaccines, virus-like particles (VLPs) have proven to be effective in humans as well as animals. VLPs mimic the structure of the virus particles they are derived from and are highly immunogenic, but they lack the virus genomic material which gives them a favorable safety profile. The…

Ori and ATMPS team to lower advanced therapy COGS through blockchain

ATMP’s blockchain-based data sharing platform will be incorporated into Ori Biotech’s cell and gene therapy manufacturing platform. ATMPS, a spin out from Farmatrust, created the Hataali platform to record scheduling and ordering data for advanced therapy treatments within a blockchain system that enables secure and confidential sharing of data between partners. Ori Biotech, a developer of automated and scalable cell and gene therapy (CGT) manufacturing systems, has partnered with ATMPS in efforts to provide improved product tracking, scheduling as well…

Abzena selects NC for $200m biologics plant

Abzena has selected Sanford, North Carolina as the site of a biologics manufacturing facility equipped with 12x 2,000 L bioreactors. In January, British contract development manufacturing organization (CDMO) Abzena announced the addition of a sixth global site in the US. The exact location of the plant was not divulged. However, the firm revealed this week that the site will be in Sanford, North Carolina. The Sanford facility will cost over $200 million and will be dedicated to manufacturing mammalian biologics.…

Roche secures space at Novartis plant as COVID drives Actemra demand

In the latest example of pandemic-related collaboration, Novartis is prepping to make the drug substance for Roche’s Actemra (tocilizumab), currently being investigated as a treatment for severe COVID-19-associated pneumonia. Novartis has signed an initial agreement with fellow Swiss pharma giant Roche to reserve capacity and implement a tech transfer for the drug substance production of Actemra (known as RoActemra in Europe) from its site in Tuas, Singapore. Actemra, a monoclonal antibody first approved in the US for rheumatoid arthritis (RA)…